Public-registry site landscape for NCT01582672, a Advanced Renal Cell Carcinoma study sponsored by Argos Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT01582672 (registry record) |
| Sponsor | Argos Therapeutics |
| Condition(s) | Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma |
| Phase | PHASE3 |
| Listed sites | 125 |
| Site countries | United States, Canada, Czechia, Hungary, Israel, Italy, Spain, United Kingdom |
Eichor generates a preliminary site-risk snapshot for NCT01582672 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →